Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as a subcutaneous injection for subcutaneous use. It is used to treat rheumatoid arthritis, severe psoriasis, certain cancers such as leukemia and lymphoma, and ectopic pregnancy. GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methofill, an antimetabolite, is employed across several disease families where rapid cell proliferation or immune activation is a problem. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases plaque formation. - Certain cancers (e.g., leukemia, lymphoma): interferes with malignant cell proliferation. - Ectopic pregnancy: terminates trophoblastic tissue to resolve the pregnancy.

Methofill may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue or general weakness. - Oral mucosal ulceration (mouth sores). - Decreased blood cell counts (anemia, leukopenia, thrombocytopenia). - Elevated liver enzymes. - Hair thinning or loss.

Serious or Rare Side Effects: - Severe liver toxicity or hepatic fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infections due to bone‑marrow suppression. - Marked bone‑marrow failure leading to pancytopenia. - Acute renal failure. - Severe cutaneous reactions such as Stevens‑Johnson syndrome.

Before initiating Methofill, several safety considerations should be addressed. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Assess renal function: adjust dose or avoid use in significant impairment. - Screen for infections: avoid initiating therapy in active infections. - Avoid pregnancy: drug is teratogenic and contraindicated in pregnant women. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal and hepatic toxicity. - Live vaccines: heightened risk of severe infection. - Trimethoprim‑sulfamethoxazole: potentiates bone‑marrow suppression. - Aminoglycoside antibiotics: may exacerbate nephrotoxicity.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect absorption and bioavailability. - Phenytoin: can reduce methotrexate efficacy. - Alcohol: increases risk of liver injury.